In today's competitive market, pricing and reimbursement strategies are key to maximizing brand success and ROI. Because every country's healthcare system is different-and every product situation is unique-every brand requires a specific access plan, tailored to each market. And you must support each plan with effective messaging that ensures strong product acceptance and uptake. Experts from TNS Healthcare spoke on this issue in a recent webinar and during an exclusive interview with Pharma Marketing News.
This article is a review of a presentation by Aaron Uydess, Senior eMarketing Manager at Novo Nordisk, made at Eye for Pharma's 3rd eCommunication and Online Marketing Summit held October 23-24, 2008, in Boston, Massachusetts. Uydess presents a best-in-class approach to developing online plans that align with strategy, reduce silos, and measure and merchandise digital strategies across a pharmaceutical marketing organization.
It's official! If the presidential election were held today, 55 percent of employees of pharmaceutical companies said they would vote for Mr. Obama and 28 percent said they would vote for Mr. McCain.
Medical device marketing is different than Rx drug marketing, which is something attendees of the recent PharmaMed Marketing & Media Conference hosted by Med Ad News learned. This article summarizes a presentation from that conference and discusses how medical device marketing to consumers and physicians is different than Rx drug marketing. While some device marketing campaigns take a page from the Rx arena, there are difficulties and roadblocks ahead and these are also summarized in this article.
This year is proving to be a critical one for many industries, including the pharma-ceutical industry. Actionable, evidence-based and global pharmaceutical competitive intelligence (CI) and general business intelligence (BI) will play an important role in the drama about to unfold. This article highlights several presentations made at the 2008 Pharmaceutical Competitive Intelligence Conference and discusses some common themes, including how environments for the pharmaceutical and device industries are changing dramatically with implications for CI going forward, the importance of keeping an eye on China, and whether CI is a strategic or tactical discipline.